PNC
GSK icon

Park National Corp’s GSK GSK Stock Holding History

Park National Corp’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,759
Closed -$205K – 319
2025
Q3 		$205K Buy
+4,759
New +$186K 0.01% 293
2022
Q3 		– Sell
-16,502
Closed -$898K – 274
2022
Q2 		$898K Buy
16,502
+149
+0.9% +$8.22K 0.04% 161
2022
Q1 		$890K Buy
16,353
+20
+0.1% +$1.09K 0.04% 166
2021
Q4 		$900K Sell
16,333
-559
-3% -$29.1K 0.04% 158
2021
Q3 		$807K Buy
16,892
+80
+0.5% +$4.02K 0.03% 167
2021
Q2 		$837K Sell
16,812
-640
-4% -$30.8K 0.04% 164
2021
Q1 		$779K Buy
+17,452
New +$792K 0.03% 167
2019
Q1 		– Sell
-4,235
Closed -$202K – 327
2018
Q4 		$202K Sell
4,235
-281
-6% -$13.8K 0.01% 294
2018
Q3 		$226K Sell
4,516
-578
-11% -$29.4K 0.01% 306
2018
Q2 		$256K Sell
5,094
-3,285
-39% -$165K 0.01% 288
2018
Q1 		$410K Buy
8,379
+1,741
+26% +$81.1K 0.02% 231
2017
Q4 		$294K Sell
6,638
-674
-9% -$31.1K 0.02% 271
2017
Q3 		$371K Buy
7,312
+162
+2% +$8.22K 0.02% 234
2017
Q2 		$385K Buy
7,150
+2,099
+42% +$112K 0.02% 227
2017
Q1 		$266K Buy
5,051
+94
+2% +$4.77K 0.02% 280
2016
Q4 		$238K Sell
4,957
-452
-8% -$22.3K 0.01% 282
2016
Q3 		$291K Buy
5,409
+133
+3% +$7.29K 0.02% 253
2016
Q2 		$286K Sell
5,276
-260
-5% -$13.7K 0.02% 263
2016
Q1 		$281K Buy
5,536
+412
+8% +$20.5K 0.02% 263
2015
Q4 		$258K Buy
+5,124
New +$261K 0.02% 268

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Park National Corp's GSK Position: Q4 2025 in Review

Park National Corp sold out of GSK (GSK) in Q4 2025, closing a stake of 4,759 shares — an estimated $205K sold.

Park National Corp first reported a position in GSK in Q4 2015 and held it in 20 quarters. The position peaked at $900K in Q4 2021. 995 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

  • Park National Corp reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
  • Park National Corp sold 4,759 GSK shares in Q4 2025, an estimated $205K.
  • Park National Corp first reported a position in GSK in Q4 2015 and held it in 20 quarters.
  • Park National Corp's GSK position peaked at $900K in Q4 2021.
  • 995 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Park National Corp's 13F filing for Q4 2025, filed 5 Jan 2026.